Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.
For over one hundred years, viruses have been recognized as capable of killing tumor cells. At present, people are still researching and constructing more suitable oncolytic viruses for treating different malignant tumors. Although extensive studies have demonstrated that herpes simplex virus type 1 (HSV-1) is the most potential oncolytic virus, therapies based on herpes simplex virus type 1 vectors still arouse bio-safety and risk management issues. Researchers have therefore introduced the new idea of treating cancer with HSV-1 mutants labeled with radionuclides, combining radionuclide and oncolytic virus therapies. This overview briefly summarizes the status and mechanisms by which oncolytic viruses kill tumor cells, discusses the application of HSV-1 and HSV-1 derived vectors for tumor therapy, and demonstrates the feasibility and prospect of HSV-1 mutants labeled with radionuclides for treating tumors.
Mi
Yan-Xia
YX
Department of Nuclear Medicine, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China.
Long
Ya-Hong
YH
Li
Yun-Chun
YC
D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009369:Neoplasms / Q000532:radiotherapy; D050130:Oncolytic Virotherapy; D011868:Radioisotopes; D011878:Radiotherapy / Q000379:methods*
D011868:Radioisotopes